Journal Mobile Options
Table of Contents
Vol. 1, No. 3, 1998
Issue release date: March 1999
Community Genet 1998;1:148–153

Toward a Framework of Mutualism: The Jewish Community in Genetics Research

Rothenberg K.H. · Rutkin A.B.
a University of Maryland School of Law, Baltimore, Md., and b Hadassah, New York, N.Y., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The ability of scientists to identify genes believed to cause inherited diseases, including familial cancers, has become considerably refined over the last two decades because of technological breakthroughs. When research published in 1995 appeared to show that genetic mutations linked to breast and ovarian cancers (BRCA1 and BRCA2) occur more frequently in Jews of Eastern European descent than in the general population, the first response among Jewish women was to rush to participate in research. When a gene linked to colorectal cancer was identified in 6% of the Jewish population in 1997, however, press reports began to carry inaccurate and inflammatory headlines about Jewish ‘mutant gene carriers’, raising fears of discrimination and loss of privacy. Some rabbis and other leaders of the Jewish community began to quietly advise Jews not to get a genetic test or participate in genetics research until legal protections against discrimination are established. At the present time, a subtle tension is developing between the Jewish tradition of encouraging the acquisition of knowledge, particularly medical knowledge (exemplified by the community’s successful collaboration with genetic researchers when tests for Tay-Sachs disease were developed in the 1970s) and the fear of potential discrimination or stigmatization. In order to address this tension, and ensure the continued participation by the Jewish community in critical genetics research, a framework based on the mutual interests of researchers and participants should be formulated. Such a framework of dialogue and policy would be useful in building an important element of trust for the Jewish community and other distinct communities who are sought for such research.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Ashkenazi signals are timely (editorial). Nature 1997;389:315.

    External Resources

  2. Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG (eds): Assessing Genetic Risks: Implications for Health and Social Policy. New York, National Academy Press, 1994.
  3. Struewing JP, Albeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198–200.
  4. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, et al: Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13:126–128.
  5. Kahn P: Coming to grips with genes and risk. Science 1996;274:496–498.
  6. Harris L: Doctor’s panel addresses Ashkenazic cancer concerns. Northern Calif Jewish Bull May 3, 1996.
  7. Ochs R: Genetic findings on breast cancer: The door’s open, researchers say, but the landscape remains murky. Newsday, May 14, 1996, Sect B, p 23.
  8. Rothenberg KH: Breast cancer, the genetic ‘quick fix’, and the Jewish community. Health Matrix 1997;7:97–124.

    External Resources

  9. Saltus R: Jewish women’s group warns of risks of cancer-gene testing. Boston Globe, Jan 17, 1997, Sect B, p 2.
  10. Stolberg SG: Concern among Jews is heightened as scientists deepen gene studies. New York Times, Apr 22, 1998, Sect A, p 24, col. 1
  11. Weiss R: Discovery of ‘Jewish’ cancer gene raises fears of more than disease. Washington Post, Sept 3, 1997, Sect A, p3.
  12. Wade N: Ideas & trends: Testing genes to save a life without costing you a job. New York Times, Sept 14, 1997, Sect A, p 5, col 3.
  13. Cohen DN: Colon cancer gene discovery prompts fear. Jewish News N J, Mar 20, 1998.
  14. Lapham EV, Kozma C, Weiss JO: Genetic discrimination: Perspectives of consumers. Science 1996;274:621–624.
  15. Geller LN, Alper JS, Billings PR, Barash CI, Beckwith J, Natowicz MR: Individual, family, and societal dimensions of genetic discrimination: A case study analysis. Sci Eng Ethics 1996;2:71–88.
  16. Kolata G: Genetic testing falls short of public embrace. New York Times, Mar 27, 1998, Sect A, p 16, col. 1.
  17. Hendren J: Stalled laws cause fear over loss of medical insurance. Associated Press, April 12, 1998.
  18. Reilly PR: Genetics, Law and Social Policy. Boston, Harvard University Press, 1977, pp 62–86.
  19. Cohen DN: Breast cancer strikes Jewish women more often than others. Kansas City Jewish Chronicle, Oct 6, 1995.
  20. Bor J: Ashkenazi Jews weather news of another gene flaw. Baltimore Sun, Sept 1, 1997; Sect B, p 1.
  21. Wadler J: Cancer redux: ‘... We didn’t know then about the ‘Jewish gene’ and ovarian cancer’. New York, Sept 15, 1997, p 26.
  22. Post ME: Curb bias against mutant-gene carriers. Newsday, Aug 27, 1997, Sect A, p 43.
  23. Schiller G: Must Read! (visited Feb 9, 1998), 34ea823.11136336
  24. Lerhman S: Jewish leaders fear gene based anti-semitism. Biotechnology Newswatch, Oct 6, 1997, p 1, col 2.
  25. Markel H: Di goldine medina (the golden land): Historical perspectives of eugenics and the East European (Ashkenazi) Jewish-American community, 1880–1925. Health Matrix 1997;7:49–64.

    External Resources

  26. Doctors launch new jewish cancer test: Amid fear and confusion, search for facts begins. Forward, March 1, 1996, p 5.
  27. Waldholz M: Scientific sleuths link colon cancer to gene in Ashkenazi Jews. Wall Street Journal Aug 26, 1997, Sect. B, p 1.
  28. Henig RM: Tricky truths about ethnicity and genetics. Washington Post, Oct 5, 1997, Sect C, p 1.
  29. Grady D: Findings on breast cancer have only complicated the puzzle. New York Times, Apr 30, 1996, Sect C, p 10, col 1.
  30. Ritter M: Genetic defect surprisingly common in Jewish women. Chicago Tribune, Oct 13, 1996, Sect: Womanews, p 9.
  31. Kaback M, Lim-Steele J, Dabholkar D, Brown D, Levy N, Zeiger K: Tay-Sachs disease-carrier screening, prenatal diagnosis, and the molecular era. JAMA 1993;270:2307–2315.
  32. Wadman M. ‘Group debate’ urged for gene studies. Nature 1998;391:314.
  33. Seachrist L: Bioethics commission grappling with stored tissue research. Bioworld Today 1997;8:204.
  34. Blank BT: To test, or not to test: The question plaguing the Jewish community. Forward, Jun 12, 1998, p 1.
  35. National Bioethics Advisory Commission Genetic Subcommittee, (transcripts) Dec 9, 1997 and Jan 6–7, 1998.
  36. Foster MW, Bernsten D, Carter TH: A model agreement for genetic research in socially identifiable populations. Am J Hum Genet 1998;63:696–702.
  37. Reilly PR: Rethinking risks to human subjects in genetic research. Am J Hum Genet 1998;63:682–685.
  38. Juengst ET: Group identity and human diversity: Keeping biology straight from culture. Am J Hum Genet 1998;63:673–677.
  39. Nation’s first formal dialogue on genetics research implications for Jewish community sponsored by Hadassah and Jewish Council for Public Affairs. Hadassah News, Apr 20, 1998.
  40. Genetic diseases & the Jewish community. Congr Monthly 1998;65(4):3–7.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50